Results 171 to 180 of about 5,282,350 (229)

PIK3CA inhibitor treatment for metastatic scrotal extramammary Paget's disease: a case report and literature review. [PDF]

AME Case Rep
Huang Y, Dong S, Ren J, Li J, Wu C, Chen H, Liu Y, Yuan J, Huang J, Xiao L.   +9 more
europepmc   +1 more source

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial. [PDF]

Oncologist
Zhang S, Ju M, Wang Q, Zhu D, Liu Z, Ye X, Li W.   +6 more
europepmc   +1 more source

Efficacy and safety of trastuzumab emtansine in patients with advanced human epidermal growth factor receptor 2-positive extramammary Paget's disease: an investigator-initiated, open-label, single-arm, multicentre, prospective, phase II clinical trial (TEMENOS-2). [PDF]

ESMO Open
Arakawa S, Hirai I, Nakamura Y, Uchi H, Ohe S, Isei T, Takenouchi T, Mori S, Takai T, Yoshikawa S, Fujimura T, Yamamoto Y, Ozaki T, Takemura R, Funakoshi T.   +14 more
europepmc   +1 more source

From Diagnosis to Therapy in Primary Cutaneous Extramammary Paget's Disease: A Systematic Review of Non-Invasive and Non-Surgical Approaches. [PDF]

Cancers (Basel)
D'Oria F, Piscazzi F, Liberi M, Foggi G, Lorini L, Calcara KM, Dika E, Valenti M, González S, Ardigò M.   +9 more
europepmc   +1 more source

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease. [PDF]

Oncologist
Zhang S, Zhou J, Zhao X, Gan H, Peng W, Li W, Sun M, Hu J, Yan W.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Extramammary Paget's disease

Journal of the American Academy of Dermatology, 1986
Summary Extramammary Paget's disease remains a difficult clinical diagnosis and, though biopsy readily establishes the presence of a tumour with an intraepidermal spread, this needs further study so that other tumours with a similar pattern of spread may be excluded. We advocate the use of a panel of readily available peroxidase-labelled antisera to
P P, Anthony, K, Freeman, A P, Warin
openaire   +4 more sources

Extramammary Paget’s Disease

New England Journal of Medicine, 2017
An 89-year-old man presented with a 1-year history of a nonhealing groin rash that did not respond to antibiotics, antifungal agents, or glucocorticoids. A diagnosis of extramammary Paget’s disease was made by means of a skin biopsy.
Sarah H, Mehrtens, Sriramulu, Tharakaram
openaire   +3 more sources

Extramammary Paget disease of the vulva

Seminars in Diagnostic Pathology, 2021
Extramammary Paget disease (EMPD) is a rare neoplasm with uncertain histogenesis, usually presenting in the anogenital area, most commonly in the vulva. The disease is characterized by slow grow and high recurrence rates. This article reviews the epidemiological, clinical, morphological, genetic and treatment features of EMPD of the vulva reported in ...
Anastasia M, Konstantinova, Dmitry V, Kazakov   +1 more
openaire   +2 more sources

Extramammary Paget's disease: a review of the literature

International Journal of Dermatology, 2018
Extramammary Paget's disease (EMPD) is a rare cutaneous malignancy. The disease typically affects older individuals aged 60–80 years and is seen most frequently in postmenopausal Caucasian women and Asian men. EMPD exhibits a predilection for the genital
Robert M Simonds, R. Segal, A. Sharma
semanticscholar   +1 more source

Mammary and extramammary Paget's disease

Journal of the European Academy of Dermatology and Venereology, 2007
Abstract Paget's disease is an intra‐epidermal adenocarcinoma seen over the nipple/areola (mammary Paget's disease) or in extramammary body zones, such as the anogenital and perineal skin and the axilla. Mammary and extramammary Paget's disease share many common clinicopathological features but also show several differences, namely ...
Jean C Kanitakis
semanticscholar   +3 more sources